Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study.
Pål André HolmeLone Hvitfeldt PoulsenClaudia TueckmantelMonika Maas EnriquezMaria Teresa Alvarez-RomanRaimondo De CristofaroPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2024)
Damoctocog alfa pegol individualized prophylaxis regimens were well-tolerated with no immunogenicity concerns. ABRs improved following the switch from pre-study prophylaxis to damoctocog alfa pegol prophylaxis. These results support the favourable safety and efficacy profile of damoctocog alfa pegol prophylaxis.
Keyphrases